Apple Unveils $1,999 Foldable iPhone Duo 
Huawei Launches Mate XT2 Foldable Phone in China 
U.S. Accuses Chinese AI Firms of Extracting Model Capabilities 
Elon Musk’s Boring Company Raises $3 Billion at $23 Billion Valuation 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Spire Healthcare Shares Jump on £1.03 Billion Takeover Deal 
TetherMax Expands into Asian Market Following Rebranding, Names Actor Yun Siyun as Brand Ambassador 
Brazil Court Suspends Sigma Lithium Mine Operations 
Nvidia-Groq AI Chip Deal Faces U.S. Antitrust Probe 
Amazon Prime Air Cargo Plane Crash Kills Five at Miami Airport 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Blackstone Eyes $2 Billion ZO Skin Health Sale 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Ingenia Rejects A$1.9 Billion Warburg Pincus Takeover Bid 
TSMC August Revenue Jumps 53% on AI Chip Demand 
Nvidia Plans 2GW Australia AI Data Center Expansion by 2027 
Add as a preferred source on Google
NEW YORK, Aug. 24, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Lipocine Inc. (“Lipocine” or “the Company”) (NASDAQ:LPCN) between June 30, 2015 and June 28, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://www.zlk.com/pslra/lipocine-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Lipocine’s filing of its New Drug Application for LPCN 1021, Lipocine’s lead product candidate, contained deficiencies; and (2) as a result, defendant’s statements about Lipocine’s business and operations were false and misleading and/or lacked a reasonable basis.
On June 29, 2016, Lipocine announced that the U.S. Food and Drug Administration had issued a Complete Response Letter regarding the Company’s New Drug Application for LPCN 1021. According to the Complete Response Letter, the FDA has identified deficiencies related to the dosing algorithm for the label and concluded the application was not ready for approval in its present form.
If you suffered a loss in Lipocine you have until August 30, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
